CTAD 2024 | The great debate: defining AD beyond amyloid-β

Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, addresses the ongoing debate over defining the etiology of Alzheimer’s disease (AD) beyond the amyloid cascade hypothesis. Recent research highlights the role of factors outside the amyloid pathway in the pathology of sporadic AD. Dr Villain underscores the importance of looking beyond amyloid-β, advocating for a definition that integrates both clinical and biological aspects of the disease. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.